SCHEDULE: Decheng Capital Discloses 8.9% Stake in Equillium

Decheng Capital and Xiangmin Cui have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 8.9% in Equillium, Inc.

Summary

• Reporting persons include Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Management IV (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, and Xiangmin Cui.
• The reporting persons collectively beneficially own 5,733,021 shares of Equillium, Inc. common stock.
• The ownership stake represents 8.9% of the company's outstanding common stock, based on 63,226,556 shares outstanding as of March 20, 2026.
• The holdings include both common stock and warrants exercisable for common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure of existing ownership, indicating stable institutional interest without signaling immediate strategic shifts.

Positives

• Significant institutional backing from a specialized life sciences investment firm.
• The filing confirms that the securities are held for investment purposes and not for the purpose of changing or influencing control of the issuer.

Negatives

• The filing indicates a concentration of ownership which could lead to volatility if the reporting persons decide to divest their position.

Risks

• Market risk associated with the underlying equity of a clinical-stage biotechnology company.
• Liquidity risk regarding the ability to exit a position of this size without impacting the share price.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a passive investment stance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings from life sciences-focused venture capital firms like Decheng Capital are standard in the biotech sector, often reflecting long-term support for clinical-stage companies as they progress through development pipelines.

Comparison to Industry Standards

• The 8.9% stake is consistent with typical venture capital ownership levels in small-cap biotechnology firms.
• The use of a joint filing agreement is standard practice for affiliated investment entities managing multiple funds.

Stakeholder Impact

• Shareholders may view the continued 8.9% stake as a sign of institutional confidence in the company's long-term prospects.

Next Steps

• Continued monitoring of future 13G/13D filings for changes in ownership status.

Key Dates

Keywords

Equillium, Decheng Capital, Schedule 13G, Biotechnology, Institutional Ownership, Equity Investment